Relevant post from Tay on twitter28 Oct 2020 07:17
A must read for holding.
Big gains mean Big profits and funds have to de-risk.
We suck it up after every growth spurt and it provides new investors an opportunity to join us.
But we need to focus on what's coming NEXT. And it's Big.
As cases reach new highs daily, Novacyt as you know has changed their strategy. R&D drive is now largely weighted towards point of need testing.
And nearly all of our catalysts coming up reflect this, let's look at them.
1. Q-TUBES
We don't know the real name for these yet, but these are magic and no other example of their kind exists in the world.
They enable Q32 users to take a sample, place it in a tube and straight to device. Child's Play. Truly revolutionary.
This is proper future tech.
2. Government Contracts
ALL major contracts in development appear to be for near patient settings.
Care Homes
Hospitals
Mining and Sports Venues
And many more, possibly even schools
EU WinterPlex
These require literally 1,000s of Q16 & Q32s for the UK alone.
Which is why we just bought the manufacturer, IT-IS.
Not because we're selling less, or scaling down, or because demand is weakening.
It's because demand is incredible globally for the highest-throughput, near-patient, multiplex-capable, portable device in the world.
That's right.
In. The. World.
And we make them right here in the UK. And we now own the whole IP for it. It's our tests Combined with it, that turns it into a wunderkind.
30 WinterPlex tests in 90 minutes.
WinterPlex. Faster than most lab 'covid-only' tech. And portable.
And soon it gets Q-TUBES.
Which means a child could literally use it.
LIterally. Take a sample, saliva, mid-nose etc (because we have 5 approved sample types now), and you just place it into the Q-TUBE.
30 of them in machine and it runs itself. Fully automated, Real Time.
Watch the results on your laptop while it runs and perform analysis.
Once Q-TUBES are mastered, they won't stop there.
This process of coating the biological components can be used for OTHER products.
And then we move onto Gen 4 in 2021.
Gen 4 is the beginning of transferring this asset onto new devices. They could anything you imagine... POC's, LFT's?
Perhaps they have already done it.
@MicrogenBioProd are teasing us. CEO says they are still innovating for covid and will launch new products soon.
They've Trademarked 2 new names.
Pro**** and Versa***
Big things are coming. Find me one company that has even remotely anywhere near the amount of catalysts and genuine growth that Novacyt has coming and deserves.
Most - if lucky, are trying to get a single product out the door.
Novacyt is moving onto Gen 3 in a single year, with Gen 4 in sight.
Nova has huge revenues coming in and M&A in sight.
One more M&A this year, and 2 in the first half of 2021.
One may be in the USA.
Novacyt has hired over 60 people already this year and over 20 are up on various recruitment sites in process.
We'r